Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
INmune Bio, Inc. INMB
$7.88
-$0.43 (-5.40%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
153047077.00000000
-
week52high
10.75
-
week52low
4.63
-
Revenue
374000
-
P/E TTM
-5172
-
Beta
1.93918200
-
EPS
-1.61000000
-
Last Dividend
0.00000000
-
Next Earnings Date
01 авг 2023 г. в 20:00
Описание компании
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| BTIG | Buy | Buy | 24 мая 2022 г. |
| B. Riley Securities | Neutral | Buy | 24 мая 2022 г. |
| B. Riley Securities | Buy | Buy | 24 янв 2022 г. |
| B. Riley FBR | Buy | 21 апр 2021 г. | |
| HC Wainwright & Co. | Buy | Buy | 25 ноя 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Moss David J | A | 1247651 | 3000 | 27 мая 2022 г. |
| Tesi Raymond Joseph | A | 1520698 | 6300 | 26 мая 2022 г. |
| Moss David J | A | 1244651 | 7700 | 26 мая 2022 г. |
| Lowdell Mark William | A | 104000 | 104000 | 22 мар 2022 г. |
| Lowdell Mark William | A | 1496383 | 23590 | 22 мар 2022 г. |
| Tesi Raymond Joseph | A | 130000 | 130000 | 22 мар 2022 г. |
| Tesi Raymond Joseph | A | 1514398 | 23724 | 22 мар 2022 г. |
| Moss David J | A | 130000 | 130000 | 22 мар 2022 г. |
| Moss David J | A | 1236951 | 17793 | 22 мар 2022 г. |
| Ganjei James Kelly | A | 35000 | 35000 | 22 мар 2022 г. |
Новостная лента
INmune Bio, Inc. (INMB) Q1 2023 Earnings Call Transcript
Seeking Alpha
03 мая 2023 г. в 22:00
INmune Bio, Inc. (NASDAQ:INMB ) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants David Moss - Chief Financial Officer RJ Tesi - Chief Executive Officer Mark Lowdell - Chief Scientific Officer Conference Call Participants Tom Shrader - BTIG Daniel Carlson - Tailwinds Research Operator Good day and welcome to the INmune Bio First Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode.
INmune Bio, Inc. to Report First Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, May 3
GlobeNewsWire
24 апр 2023 г. в 09:00
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, April 24, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient's innate immune system to fight disease, today announced that it will host a conference call on Wednesday, May 3, 2023 at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2023 and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.
INmune Bio: Alzheimer's Disease Treatment Lottery Ticket
Seeking Alpha
24 апр 2023 г. в 05:00
INmune Bio: Alzheimer's Disease Treatment Lottery Ticket.
INmune Bio, Inc. to Present Preclinical Data at the 2023 AACR Annual Meeting Showing Improved Outcomes in High-Risk Breast Cancer by Targeting MUC4 Expression with INB03
GlobeNewsWire
11 апр 2023 г. в 08:00
Two presentations show targeting high-risk MUC4 expressing HER2+ and Triple Negative Breast Cancer with INB03 reverses resistance mechanisms to immunotherapy
INmune Bio, Inc. (INMB) Q4 2022 Earnings Call Transcript
Seeking Alpha
03 мар 2023 г. в 02:51
INmune Bio, Inc. (NASDAQ:INMB ) Q4 2022 Earnings Conference Call March 2, 2023 4:30 PM ET Company Participants David Moss - CFO RJ Tesi - CEO CJ Barnum - Head of Neuroscience Mark Lowdell - Chief Scientific Officer Conference Call Participants Jason McCarthy - Maxim Group Tom Shrader - BTIG Daniel Carlson - Tailwinds Research Operator Greetings, and welcome to the INmune Bio Fourth Quarter and Full Year 2022 Earnings Call. This conference will be recorded.